Survival of nationally shared, HLA-matched kidney transplants from cadaveric donors. The UNOS Scientific Renal Transplant Registry

The New England Journal of Medicine
S TakemotoD W Gjertson


The importance of HLA histocompatibility typing to the outcome of transplantation of cadaveric kidneys has been controversial. Four years ago, a prospective trial began in all U.S. transplantation centers to determine whether the results of transplantation would improve with the nationwide shipment of kidneys from cadaveric donors to waiting patients undergoing dialysis when there was a match at the HLA-A, B, and DR loci. A total of 1386 cadaveric kidneys were shipped from 108 organ centers to 198 transplantation centers and distributed among HLA-matched recipients, 1004 of whom were receiving a first transplant and 382 of whom were receiving a subsequent transplant. Graft survival in these recipients was compared with that in 22,188 recipients of first transplants and 3950 recipients of subsequent transplants whose HLA antigens differed from those of the donor. The rate of graft survival at one year in recipients of HLA-matched first transplants was 88 percent, as compared with 79 percent in the recipients of mismatched grafts (P less than 0.001). The estimated half-life of the kidney after the first year was 17.3 years for matched grafts, as compared with 7.8 years for mismatched grafts (P = 0.003). Among paired kidneys from ...Continue Reading


Apr 11, 1991·The New England Journal of Medicine·D W GjertsonM R Mickey
Mar 1, 1991·Kidney International·P I Terasaki
Feb 1, 1989·Transplantation·M R MickeyP I Terasaki
May 19, 1988·The New England Journal of Medicine·G Opelz
May 1, 1987·Transplantation·W R GilksP T Klouda

❮ Previous
Next ❯


Oct 23, 1993·Lancet·M M FriedlaenderA Eid
Mar 27, 2001·Transplantation Proceedings·M LangP Neuhaus
Aug 11, 2001·Transplantation Proceedings·A BarbariA Barakeh
Nov 20, 1997·Transplantation Proceedings·H U KlehrD Heimbach
Sep 2, 1998·Transplantation Proceedings·M LangP Neuhaus
Dec 29, 1998·Transplantation Proceedings·A Szabo, U Heemann
Jan 5, 2000·Transplantation Proceedings·M GokhanM Haberal
Feb 19, 1994·Lancet·J EganA Woodcock
Aug 1, 1997·Human Immunology·J M Cecka
Jan 1, 1995·Eye·C J Taylor, P A Dyer
Nov 1, 1993·Nature Genetics·S Martin, P A Dyer
Nov 26, 1999·Kidney International·Y W SijpkensL C Paul
Nov 13, 2001·Kidney International·C F Zayas, A Guasch
Sep 17, 1992·The New England Journal of Medicine·W E Braun
Jan 21, 1993·The New England Journal of Medicine·A J Fabrega, R Pollak
Aug 11, 1994·The New England Journal of Medicine·M Suthanthiran, T B Strom
Sep 22, 1994·The New England Journal of Medicine·S TakemotoJ M Cecka
Feb 6, 1997·The New England Journal of Medicine·P J Hauptman, K J O'Connor
Nov 5, 1999·The New England Journal of Medicine·M A SchnitzlerD C Brennan
Oct 12, 2000·The New England Journal of Medicine·S K TakemotoJ M Cecka
Nov 23, 2000·The New England Journal of Medicine·C J Young, R S Gaston
Oct 30, 2001·The New England Journal of Medicine·K C MangeR D Bloom
Jun 15, 1996·Transplantation·J D PirschF O Belzer
Jul 15, 1997·Transplantation·H I FeldmanR A Grossman
May 16, 1998·Transplantation·M FischerederW Land
Feb 12, 1999·Transplantation·F L DelmonicoR J Rohrer
Aug 19, 2000·Transplantation·C S HollenbeakM A Schnitzler
Mar 10, 2001·Transplantation·H U Meier-KriescheB Kaplan
Sep 28, 2002·Transplantation·Mark D StegallUNKNOWN Organ Procurement and Transplantation Network/United Network for Organ Sharing Kidney/Pancreas Transplantation Committee
Oct 23, 2003·Ultrasound Quarterly·Grant M Baxter
Mar 14, 2008·Transplantation·Gopal BasuGeorge T John
Mar 1, 1995·Tissue Antigens·M Fernandez-ViñaP Stastny

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.